JAMP Pharma Group Expands Oncology Portfolio with PrJAMP Enzalutamide [Yahoo! Finance]
ASTELLAS PHARMA UNSP/ADR (ALPMY)
NASDAQ:AMEX Investor Relations:
astellas.com/jp/en/investors
Company Research
Source: Yahoo! Finance
JAMP Pharma Group is launching Pr JAMP Enzalutamide, a generic alternative to the reference product Pr Xtandi® (marketed in Canada by Astellas Pharma Canada Inc.). With the largest selection of generic medications in Canada , JAMP Pharma Group is proud to offer a new, lower-cost therapeutic option for patients with prostate cancer. JAMP Pharma Group has recognized expertise in oncology therapies, now featuring 12 specialty products. The JAMP Care™ program stands out for its specialized teams and its ability to provide highly differentiated services, ensuring tailored support for each patient and effective collaboration with every care team. BOUCHERVILLE, QC March 16, 2026 /CNW/ - The JAMP Pharma Group, a leader in the Canadian pharmaceutical industry, announces the launch of Pr JAMP Enzalutamide (Enzalutamide oral capsules) in Canada, strengthening its commitment to improving access to critical prostate cancer therapies. With this launch, JAMP consolidates its role as a trust
Show less
Read more
Impact Snapshot
Event Time:
ALPMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALPMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALPMY alerts
High impacting ASTELLAS PHARMA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ALPMY
News
- Astellas Pharma (ALPMY) was upgraded by Jefferies Financial Group Inc. from "hold" to "strong-buy".MarketBeat
- IsomAb appoints Dr Philip Brainin as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- BioNTech's Founding Duo Will Leave to Start New mRNA Firm [Yahoo! Finance Canada]Yahoo! Finance Canada
- BioNTech's Founding Duo Will Leave to Start New mRNA Firm [Yahoo! Finance]Yahoo! Finance
- Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? [Yahoo! Finance]Yahoo! Finance